Skip to main content
. 2016 Aug 6;7(37):60446–60460. doi: 10.18632/oncotarget.11108

Figure 3. Myricetin reduces the expression of cyclin D1 and PCNA in intestinal adenomatous polyps.

Figure 3

A. (Left) Immunohistochemical staining shows numerous cyclin D1- positive cells in the small intestinal and colonic adenomatous polyps of vehicle control mice as compared to myricetin-treated mice (×400, local area). (Right) Bar graphs of cyclin D1-positive cell counts. B. (Left) Western blots of lysates from myricetin-treated mice show decreased cyclin D1 expression in the small intestinal and colonic adenomatous polyps as compared to vehicle controls. (Right) Band intensity as quantified by densitometry and normalized to β-actin. C. (Left) Myricetin decreased PCNA-positive cells as determined by immunohistochemical staining (×400, local area). (Right) Bar graphs of PCNA-positive cell counts. D. Western blot analysis shows reduced PCNA expression in the small intestinal and colonic adenomatous polyps of myricetin-treated mice as compared to vehicle controls. (Right) Band intensity as quantified by densitometry and normalized to β-actin. Bars represent means ± S.D. of six mice. **, p < 0.01 vs. vehicle control. Experiments were performed in triplicate.